With high drug prices creating widespread controversy, top pharmaceutical companies and their trade group vastly increased their lobbying spending on Capitol Hill.
Doctors are beginning to pay attention to injuries, such as brain damage or kidney failure, that can afflict people who survive an overdose.
Nearly half of state hospitals received a grade of C or lower for patient safety on a report card aimed at prodding them to do more to prevent injuries and deaths.
Led by Pfizer and Amgen, about 10 health care firms contributed to President Donald Trump’s inauguration, which earned them entry into private events with the president and vice president.
Readers react to and comment on recent stories.
The advocacy group behind an expensive media blitz opposing Canadian drug imports has deep ties to the drug industry’s largest trade group.
The powerful chairman of the Senate Judiciary Committee wants the Centers for Medicare and Medicaid Services to explain $125 million in overcharges by insurers.
The nonprofit Leapfrog Group shows nearly half of California hospitals got a grade of C, D or F in patient safety measures — an increase from two years ago.
In a region where bears outnumber people, a small medical facility sets a modern example for hospitals on life support.
Such efforts have previously failed in the face of opposition from the drug industry, which questions their effectiveness and contends prices reflect research and development costs.